Key highlights
- Syntara (ASX:SNT) paused recruitment in its Phase 1b study of SNT-9465.
- The company received reports of mild to moderate skin irritation in some participants.
- A review of unblinded data will inform whether recruitment resumes or the study is discontinued.
Syntara (ASX:SNT) fell 10.35% to AUD 0.013 during the 20 November 2026 session. The benchmark S&P/ASX 200 was also down during the session. The company, a clinical-stage drug developer, reported a pause in recruitment in its Phase 1b skin scarring study on 10 November 2026.
Recruitment paused after an internal review
On 10 November 2026, Syntara announced a pause in enrolment in its trial of topical SNT-9465 in people with hypertrophic sternotomy scars. The company took the step after reviewing local tolerability findings in its blinded trial population. It reported mild to moderate irritation in some participants. The disclosure identifies a tolerability observation under review and gives no breakdown by study group. Syntara’s immediate decision concerned bringing new participants into the study. It said the next assessment would examine information from both people who had completed participation and those still in the trial.
What unblinding adds to the study review
Syntara plans to review the available data after unblinding, when assignment to study groups can be taken into account. The company said the review will inform a choice between resuming recruitment and discontinuing the study. Its November release does not provide how many participants reported irritation or its incidence in the different study groups. Those details affect how the observations can be interpreted. The company also said it would review all collected trial data to help assess the approach. The outcome of that review is a separate development from the initial decision to pause enrolment.
An additional site preceded the decision
Before the pause, Syntara said feedback from participants and trial sites had supported expanding recruitment, including opening another clinical site to meet its timelines. The decision in November followed the subsequent review of tolerability observations. Those activities address separate aspects of conducting the study. Site participation determines where recruitment takes place, while emerging data can influence whether recruitment proceeds. The previously reported expansion does not establish when new enrolment can resume. Syntara expected to complete its review during the quarter in which it made the announcement.
The blinded reports date from the ongoing Phase 1b study, so they cannot establish how frequent the observation was among participants assigned to the investigational candidate.
The scarring study is one program in a wider portfolio
The November update also described separately reported work on amsulostat for myelofibrosis. Syntara said that candidate had completed a Phase 2a trial, including use as a monotherapy and in combination with a JAK inhibitor. It also reported the initiation of two Phase 1c/2 studies in myelodysplastic syndrome. The company described FDA Fast Track and Orphan Drug designations and investigational clearance for the myelofibrosis program. Those designations relate to that candidate and to its development in that setting. The recruitment decision described in the update concerns SNT-9465 and the hypertrophic scar population. Syntara also reported work on a separate candidate with Parkinson’s UK. That collaboration concerns a different development programme from the scar study and is not part of the announced recruitment review.
How the trial fits Syntara’s development work
Syntara described SNT-9465 as a topical candidate being evaluated for scarring. The participants in the reported trial have hypertrophic scars following sternotomy. The company also described ongoing work with the University of Western Australia and Professor Fiona Wood on keloid scars. That work is a separate collaboration, with a different focus from the enrolment decision announced on 10 November. The company’s broader research spans conditions linked to fibrosis or inflammation, as well as blood cancers. It previously developed two respiratory products that it sold in October 2023. The latest update concerns a trial of one investigational candidate and the local tolerability data collected in that setting. For subsequent reporting, the relevant developments are completion of the data review, the decision about the trial and any further information Syntara provides on the observed irritation.
What the company expects to decide
The next stated milestone is completion of the unblinded review. Its findings will inform the decision about enrolment and may add detail about the local observations in the study population. The release did not set a date for any restart. Any later schedule will depend on the outcome of the review and the decision Syntara makes about the program.






Please wait processing your request...